Off-pump coronary artery bypass

New Study Demonstrates Retia Medical's Multi-Beat Analysis (MBA™) Algorithm is More Accurate Than a Competing Cardiac Output Monitoring Technology in Cardiac Surgery

Retrieved on: 
Friday, July 16, 2021
Clinical medicine, Medicine, Medical specialties, Cardiac surgery, Pulmonary artery catheter, Cardiac output, Off-pump coronary artery bypass, Coronary artery bypass surgery, Heart, Cardiothoracic anesthesiology, Cardiac catheterization

The measurements from each monitor were compared to the reference, thermodilution measurements from an invasive, pulmonary artery catheter (PAC).

Key Points: 
  • The measurements from each monitor were compared to the reference, thermodilution measurements from an invasive, pulmonary artery catheter (PAC).
  • "The Argos device is superior to other non-invasive cardiac output monitors on the market and remains precise across a myriad of conditions.
  • Off-pump coronary artery bypass graft surgery is a challenging cardiac surgery where patients experience significant hemodynamic variations.
  • Retia Medical's Argos Monitor, with its Multi-Beat Analysis (MBATM) algorithm, eliminates a critical problem with older cardiac output technologies.

Vascular Graft Solutions Wins FDA approval to Market the VIOLA™ Clampless Proximal Anastomosis System for CABG

Retrieved on: 
Monday, March 1, 2021
Medical specialties, Anatomy, Clinical medicine, Cardiac surgery, Coronary artery bypass surgery, Vascular bypass, Aorta, Ascending aorta, Anastomosis, Off-pump coronary artery bypass, Open aortic surgery

TEL AVIV, Israel, March 1, 2021 /PRNewswire/ -- Vascular Grafts Solutions (VGS) Ltd. announced today receipt of marketing clearance from the Food and Drug Administration (FDA) for the VIOLA, a new device for clampless proximal anastomosis in coronary artery bypass grafting (CABG).

Key Points: 
  • TEL AVIV, Israel, March 1, 2021 /PRNewswire/ -- Vascular Grafts Solutions (VGS) Ltd. announced today receipt of marketing clearance from the Food and Drug Administration (FDA) for the VIOLA, a new device for clampless proximal anastomosis in coronary artery bypass grafting (CABG).
  • Neurocognitive dysfunction remains the most devastating perioperative complication of CABG and frequently attributed to atheroembolism that originate from the ascending aorta.
  • The VIOLA device minimizes aortic manipulation during on and off-pump CABG and enable cardiac surgeons to perform protected, clean, and dry proximal anastomosis without partial clamping the aorta.
  • VIOLA is a new generation of clampless proximal anastomosis system that combines a standard punching mechanism with optimal sealing during anastomosis construction.

Treasure Coast Region's Top Cardiac Surgeon Joins Jupiter Medical Center

Retrieved on: 
Wednesday, August 26, 2020
Medical specialties, Surgery, Clinical medicine, Cardiac surgery, Surgical specialties, Cardiothoracic surgery, Thoracic surgery, Off-pump coronary artery bypass

JUPITER, Fla., Aug. 26, 2020 /PRNewswire/ --Jupiter Medical Center, ranked number one for safety, quality and patient satisfaction in Palm Beach County and the Treasure Coast region, welcomes Arthur Katz, M.D., as the medical director of cardiac surgery at the Robson Heart & Vascular Institute and Timothy and Jayne Donahue Cardiac Surgery Program at Jupiter Medical Center.A board-certified adult cardiac surgeon, Dr. Katz is highly regarded as a national leader in off-pump coronary artery bypass surgery.

Key Points: 
  • JUPITER, Fla., Aug. 26, 2020 /PRNewswire/ --Jupiter Medical Center, ranked number one for safety, quality and patient satisfaction in Palm Beach County and the Treasure Coast region, welcomes Arthur Katz, M.D., as the medical director of cardiac surgery at the Robson Heart & Vascular Institute and Timothy and Jayne Donahue Cardiac Surgery Program at Jupiter Medical Center.A board-certified adult cardiac surgeon, Dr. Katz is highly regarded as a national leader in off-pump coronary artery bypass surgery.
  • "Dr. Katz is a gifted surgeon with an impressive track record of outstanding surgical outcomes and we are honored to have him join us as the medical director of cardiac surgery," said Dr. Amit Rastogi, president and CEO of Jupiter Medical Center.
  • Dr. Katz has earned a highly respected name among his peers and patients and is considered the pulse of the new cardiac surgery program at Jupiter Medical Center.
  • Prior to joining Jupiter Medical Center, Dr. Katz worked as a cardiothoracic surgeon at Palm Beach Gardens Medical Center and Boca Raton Regional Hospital.

Outlook on the Worldwide Coronary Artery Bypass Grafts Industry to 2025 - Featuring Abbott, Boston Scientific & Edwards Lifesciences Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 26, 2020
Health, Medical devices, Cardiology, Medicine, Cardiac surgery, Medical specialties, Clinical medicine, Coronary artery bypass surgery, Coronary arteries, Off-pump coronary artery bypass, Minimally invasive cardiac surgery

The "Coronary Artery Bypass Grafts (CABG) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Coronary Artery Bypass Grafts (CABG) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • An unusual period in history, the coronavirus pandemic has unleashed a series of unprecedented events affecting every industry.
  • The On-Pump or Traditional Coronary Artery Bypass Grafting market will be reset to a new normal which going forwards in a post COVID-19 era will be continuously redefined and redesigned.
  • In Japan, the On-Pump or Traditional Coronary Artery Bypass Grafting segment will reach a market size of US$5 by the close of the analysis period.

CytoSorb® is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.

Retrieved on: 
Thursday, January 30, 2020
Medicine, Cardiac surgery, Medical specialties, Clinical medicine, Coronary artery bypass surgery, Ticagrelor, Cardiopulmonary bypass, Acute coronary syndrome, Off-pump coronary artery bypass

Mr. Vincent Capponi, Chief Operating Officer of CytoSorbents stated, "CytoSorb is the only approved therapy to remove ticagrelor in the European Union and in all 58 countries where CytoSorb is distributed.

Key Points: 
  • Mr. Vincent Capponi, Chief Operating Officer of CytoSorbents stated, "CytoSorb is the only approved therapy to remove ticagrelor in the European Union and in all 58 countries where CytoSorb is distributed.
  • CytoSorb is easily installed into a side circuit of the heart-lung machine during cardiopulmonary bypass, and has been used safely in thousands of cardiac surgeries for other reasons to date."
  • Overall, the 1.1 million hospital admissions annually for acute coronary syndrome in the U.S. drives approximately 400,000 CABG procedures each year.
  • In the European Union, there are approximately 250,000 CABG procedures annually, with nearly 100,000 in Germany alone.

John Mack, Medtronic, Minneapolis, named chair of American Heart Association's Twin Cities Board

Retrieved on: 
Monday, November 11, 2019
Medicine, Cardiac surgery, Medtronic, Off-pump coronary artery bypass, Minneapolis, Cannula

MINNEAPOLIS, Nov. 11, 2019 /PRNewswire/ -- John Mack, VP and general manager of Medtronic's Cardiac Surgery business, was elected chair of the American Heart Association's Twin Cities Board, for a two-year term.

Key Points: 
  • MINNEAPOLIS, Nov. 11, 2019 /PRNewswire/ -- John Mack, VP and general manager of Medtronic's Cardiac Surgery business, was elected chair of the American Heart Association's Twin Cities Board, for a two-year term.
  • "We are honored to have John's expertise and leadership to guide us into the future," said Holly Messick, executive director of the American Heart Association in Minnesota.
  • Mack will head up a group of 24other local healthcare professionals and business and community leaders on the Twin Cities Board.
  • At Medtronic, Mack oversees the cardiopulmonary, blood management, cannula, MICS, OpCab, ablation, surgical heart valves and repair businesses.

RETIA MEDICAL Announces Two Publications of Independent Validation Studies of its Argos Cardiac Output Monitor in off-pump coronary artery bypass surgical (OR) patients and high-risk post-cardiac surgical patients in the ICU

Retrieved on: 
Wednesday, September 4, 2019
Medical specialties, Medicine, Clinical medicine, Cardiac surgery, Off-pump coronary artery bypass, Coronary artery bypass surgery, Monitoring, Cardiac output, Intensive care unit, Intensive care medicine

VALHALLA, N.Y., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Retia Medical, LLC announced today the recent publications of two independent validation studies which confirmed the accuracy of the minimally invasive Argos Hemodynamic Monitor for monitoring cardiac output in off-pump cardiac bypass graft (OPCAB) patients during their OR procedures and recovery in the CTICU.

Key Points: 
  • VALHALLA, N.Y., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Retia Medical, LLC announced today the recent publications of two independent validation studies which confirmed the accuracy of the minimally invasive Argos Hemodynamic Monitor for monitoring cardiac output in off-pump cardiac bypass graft (OPCAB) patients during their OR procedures and recovery in the CTICU.
  • In two studies led by Bernd Saugel, MD from the University Medical Center Hamburg-Eppendorf in Hamburg, Germany, clinicians compared 572 paired (before/after intervention) CO measurements of a total of 58 OPCAB surgical patients and 167 paired (before/after intervention) CO measurements of 31 Intensive Care Unit patients.
  • We are grateful to have had the opportunity to provide the Argos monitor to Dr. Saugel and his team, who led an especially rigorous test of the performance of our monitor.
  • Retia Medical designed the Argos Cardiac Output (CO) Monitor to provide members of the Critical Care team in the operating room and intensive care unit with a more accurate, intuitive and affordable hemodynamic monitor that supports confident, data-based patient care decision making.

Deborah Heart and Lung Center among Top 7% in the Nation for Heart Surgery

Retrieved on: 
Thursday, December 20, 2018
Medicine, Surgery, Cardiac surgery, Thoracic surgery, Surgical specialties, Society of Thoracic Surgeons, Coronary artery bypass surgery, Cardiothoracic surgery, Deborah Heart and Lung Center, Off-pump coronary artery bypass, Minimally invasive cardiac surgery

BROWNS MILLS, N.J., Dec. 20, 2018 /PRNewswire/ --Deborah Heart and Lung Center is among the top 7% in the nation for heart surgery, as rated by the Society of Thoracic Surgeons (STS).

Key Points: 
  • BROWNS MILLS, N.J., Dec. 20, 2018 /PRNewswire/ --Deborah Heart and Lung Center is among the top 7% in the nation for heart surgery, as rated by the Society of Thoracic Surgeons (STS).
  • Deborah -- New Jersey's only specialty heart hospital -- has received a distinguished three-star rating from the STS for its patient care and outcomes in isolated coronary artery bypass grafting (CABG) surgery.
  • The star rating is calculated using a combination of quality measures for specific procedures performed by an STS Adult Cardiac Surgery Database participant.
  • This is an especially noteworthy achievement since in addition to cardiac disease Deborah patients often have many other health-related issues.

John Radcliffe Oxford University Hospital is the First Medical Center in the UK to Use VEST Technology in Patients Undergoing Coronary Bypass Surgery

Retrieved on: 
Wednesday, August 1, 2018
Medicine, Clinical medicine, Surgery, Cardiac surgery, Coronary artery bypass surgery, Vascular bypass, Bypass surgery, Coronary artery disease, Hybrid coronary revascularization, Off-pump coronary artery bypass

TEL AVIV, Israel, Aug. 1, 2018 /PRNewswire/ -- Vascular Graft Solutions announces today that John Radcliffe hospital in Oxford, is the first center in the UK to use its VEST technology to externally support vein grafts in patients undergoing coronary bypass surgery.

Key Points: 
  • TEL AVIV, Israel, Aug. 1, 2018 /PRNewswire/ -- Vascular Graft Solutions announces today that John Radcliffe hospital in Oxford, is the first center in the UK to use its VEST technology to externally support vein grafts in patients undergoing coronary bypass surgery.
  • "Recent major trials have ended the long standing debate regarding the relevance of bypass surgery in the era of less invasive treatment options and concluded that bypass surgery remains the best treatment option for patients with severe coronary disease."
  • Prof. Taggart continues: "Performing state of the art bypass surgery and advancing clinical research is our commitment to patients.
  • VEST is CE marked and was implanted successfully in more than 2,000 patients and is commercialized in several countries.

Coronary Artery Bypass Graft Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Retrieved on: 
Wednesday, June 13, 2018
Medicine, Cardiac surgery, Clinical medicine, Surgery, Coronary artery bypass surgery, Endoscopic vessel harvesting, Bypass surgery, Off-pump coronary artery bypass, Minimally invasive direct coronary artery bypass surgery

NEW YORK, June13, 2018 /PRNewswire/ -- Global Coronary Artery Bypass Graft Market: Overview

Key Points: 
  • NEW YORK, June13, 2018 /PRNewswire/ -- Global Coronary Artery Bypass Graft Market: Overview
    This report analyzes the current and future scenario of the global coronary artery bypass graft market.Increase in incidence of cardiovascular diseases, rise in adoption of endoscopic surgeries, favorable reimbursement policies, surge in medical tourism, and technological advancements are factors expected to drive the global coronary artery bypass graft market during the forecast period.
  • Global Coronary Artery Bypass Graft Market: Key Segments
    Based on product type, the global coronary artery bypass graft market has been segmented into on-pump CABG, off-pump CABG, minimally invasive direct CABG, and conventional CABG.
  • Based on technique, the global coronary artery bypass graft market has been bifurcated into traditional vessel harvesting and endoscopic vessel harvesting.
  • The global coronary artery bypass graft market has been segmented as follows:
    Global Coronary Artery Bypass Graft Market, by Product Type